Heraldnet.com
SUNDAY, SEPTEMBER 5, 2010 2:14 pm
LocalNorthwestNation & WorldPoliticsSpecial ReportsPhotosColumnistsMultimedia 
Blog
Michelle Dunlop
787 goes to extremes
Blog
Amy Rolph
25 years for Northwest Software Technologies of Everett
Mike Benbow
Business editor Mike Benbow's insights into all things business.
•Latest: A wary take on health care bill
Steve Tytler
Steve Tytler answers your questions about real estate.
•Latest: What to do when surveys conflict
 
WEEK IN REVIEW
Saturday
Team of detectives investigate death of Sultan ...
Man dead after encounter with deputies in Gold Bar
Three people killed in wreck on Whidbey Island
Friday
3 killed in crash on Whidbey Island
Accident closes part of Highway 20
Bail set at $1 million for man in pursuit
Thursday


Man accused of shooting at police had allegedly...
Lynnwood notifies more than 100 employees of po...
New temporary police chief named in Granite Falls
Wednesday


A stroke of kindness for Everett woman
Suspect arrested in Everett manhunt after shots...
New student exams, familiar results
Tuesday


Crash leaves car embedded in Everett Transit bus
County students get mixed grade from superinten...
Stevens Hospital District taxes to stay
Monday


More than a nuisance
Mukilteo's red-light camera fight on radar of ...
Renamed Keystone ferry terminal a coup for Coup...
Sunday


Snohomish County becomes a destination for airp...
You’ll need only 1 flu shot this year
Snohomish County YMCA goal: Healthy kids
 

ADVERTISEMENT

Business   Print This Article  Email This Page  Subscribe Now! facebook digg reddit del.icio.us fark stumble

 
 
CONTACT THE HERALD
Mike Benbow, Business Editor
benbow@heraldnet.com
 
Published: Friday, June 16, 2006

Bothell firm in the money

Venture investors back MediQuest Therapeutics Inc.'s efforts with $16 million in capital.

BOTHELL - MediQuest Therapeutics Inc., a biotechnology company that is developing treatments for mostly overlooked conditions, has raised $16 million in its first try at wooing venture capitalists.

Fred Dechow, chief executive officer of the Bothell firm, said MediQuest initially had hoped to raise $10 million, but was delighted to find stronger-than-expected interest from venture investors.

Launched in Seattle 12 years ago, MediQuest has honed its focus to pharmaceutical treatments for infectious and inflammatory skin conditions. Its lead drug candidate is for Raynaud's phenomenon, a disease that causes pain in the fingers and toes of at least 6 million Americans.

MediQuest's patented gel for that condition is in a late-stage phase-3 trial. In earlier tests of the potential drug, it demonstrated effectiveness within five minutes of application.

The venture money will help with that and the rest of the regulatory approval process.

"This will continue that development, and should get us to the point where we are ready to file a new drug application on our lead product," Dechow said.

Additionally, the new cash also will help him fill out the company's management team, which lacks a chief financial officer and managers to oversee clinical and medical affairs.

The company also is testing a topical gel that may be effective against the most prevalent form of toenail fungus.

Additionally, MediQuest is working on cosmetic-type products that don't require the same long-term regulatory approval process. Those include a hair-growth control compound that slows the growth of underarm hair. An unidentified Fortune 100 company has signed a research and development contract for that product.

Seattle-based Integra Ventures and Novo A/S of Denmark jointly led the venture investment, with Janus and Masa Life Science Ventures also taking part. Soren Schifter of Novo A/S and A. Sinclair Dunlop of Masa will join MediQuest's board of directors as a result. Joseph Piper of Integra Ventures will become the company's new chairman.

Reporter Eric Fetters: 425-339-3453 or fetters@heraldnet.com.

Other Advertisers
TODAY'S TOP JOBS
 View All Top Jobs 
Top Cars
Top Homes

ADVERTISEMENT